Dr. Frost talks about the results of the Halozyme study and the positive results, including a drop in A1c from the 8 range in type 2 diabetes patients to around 6.8. He also lets us know how the reduced use of better-designed insulins could even result in some weight loss, as patients need less insulin to control their blood sugars.
More videos with Dr. Frost:
Dr. Gregory Frost co-founded Halozyme in 1999 and has spent more than fifteen years conducting research on the extracellular matrix. During his eleven years at Halozyme, Dr. Frost has led the R&D efforts from discovery through FDA approval for a number of biotechnology products, and was named President and CEO in December 2010. From 1998 to 1999, he was a scientist at the Sidney Kimmel Cancer Center (SKCC), where he focused much of his work on studying tumor physiology and developing enzyme platform technologies. Prior to SKCC, his research in the Department of Pathology at the University of California, San Francisco, led directly to the purification, cloning, and characterization of the human hyaluronidase gene family, and the discovery of several metabolic disorders. He has authored multiple scientific peer-reviewed and invited articles in the hyaluronidase field and is an inventor on several key patents. Dr. Frost is a member of the American Association for Cancer Research and the American Society of Clinical Oncology and he is registered to practice before the U.S. Patent and Trademark Office. Dr. Frost earned his B.A. in biochemistry and molecular biology from the University of California, Santa Cruz, and his Ph.D. in the Department of Pathology at the University of California, San Francisco.
For more information, please visit the Halozyme website.